Physician profile
Michael A Amadei
NPI 1487692364
$657.45
in general payments reported to CMS, 2019-2025
15 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $409 · 2020: $40.88 · 2021: $143 · 2022: $64.64.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $173.00 | 2019-2021 | |
| Amarin Pharma, INC. | $159.29 | 2019 | |
| Abbvie INC. | $64.64 | 2022 | |
| Abbott Laboratories | $38.71 | 2019 | |
| Horizon Therapeutics Plc | $36.37 | 2021 | |
| Janssen Pharmaceuticals, INC | $29.78 | 2019-2021 | |
| Bayer Healthcare Pharmaceuticals INC. | $24.61 | 2021 | |
| Novo Nordisk INC | $22.05 | 2021 | |
| Biohaven Pharmaceuticals, INC. | $20.11 | 2021 | |
| Novartis Pharmaceuticals Corporation | $17.34 | 2019 | |
| Mylan Specialty L.P. | $17.16 | 2019 | |
| Radius Health, INC. | $15.95 | 2019 | |
| Teva Pharmaceuticals USA, INC. | $15.52 | 2019 | |
| Esperion Therapeutics, INC. | $11.67 | 2021 | |
| Allergan, INC. | $11.25 | 2020 |
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Michael Amadei listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.